Neuralink Value Nears $42 Billion in Secondary Trading

FREMONT, Calif. — Neuralink's market value has climbed toward $42 billion in secondary trading, a dramatic re-rating of Elon Musk's brain-computer interface company that reflects surging investor demand as its human trials expand across multiple continents.

The figure, reported this week by market-intelligence trackers and echoed across financial data providers, marks a steep rise from the roughly $9 billion valuation attached to Neuralink's last official funding round little more than a year ago. The company raised a $650 million Series E in early 2026, and shares held by early backers and employees have since become some of the most sought-after private paper in tech.

What Is Driving the Re-Rating

Investors are paying up for one reason: clinical momentum. Neuralink has moved from a single implant recipient to a growing roster of patients, and its trials have broadened from cursor control to more ambitious goals. As we reported when Neuralink's CONVOY trial extended brain control to a robotic arm, the company is steadily proving that its threads can do more than move a pointer on a screen.

Each new milestone widens the addressable market. A device that restores movement, speech or sight would serve millions of patients, and Neuralink has begun trials aimed at all three. That optionality — a single platform targeting paralysis, ALS and blindness — is exactly the kind of story that pulls secondary buyers off the sidelines.

A Pipeline That Keeps Widening

The company's roadmap has expanded quickly through 2026. Its VOICE trial is working to decode speech directly from neural activity, and its Blindsight program is preparing implants intended to restore a basic form of vision. Our coverage of Neuralink's push toward a first Blindsight implant laid out just how far the science has come in a short window.

Behind the trials sits a manufacturing effort designed for scale. Neuralink has leaned on its R1 surgical robot to automate implant procedures, a prerequisite for moving from dozens of patients to thousands. Details on the company's trials and technology are published on Neuralink's official site.

The Bigger Picture

Neuralink remains privately held, so the $42 billion figure reflects secondary transactions rather than a formal fundraising valuation. Still, the gap between that number and the company's last primary round signals how the market is pricing in the possibility of regulatory clearances and a far larger patient base ahead.

If the clinical results keep landing, expect Neuralink's next official raise to validate — and potentially exceed — the enthusiasm already visible in the secondary market, cementing its place among the most valuable private companies in the Musk orbit.